Cifirate Tablet
Ciprofibrate
100 mg
Opsonin Pharma Limited
| Pack size | 30's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 15.00 AED |
Indications
Cifirate Tablet is used for:
Hypertriglyceridaemia, Mixed hyperlipidaemia
Adult Dose
Oral
Hyperlipidaemias
Adult: 100 mg daily.
Child Dose
Renal Dose
Renal Impairment
CrCl (mL/min) Dosage
<30 Contraindicated.
30-80 Reduce dose to 100 mg every other day.
Administration
May be taken with or without food.
Contra Indications
Severe hepatic impairment.
Severe renal impairment.
Pregnancy and lactation, or when pregnancy is suspected.
Concurrent use with another fibrate.
Hypersensitivity to the active substance or to any component of the product.
Precautions
Patient with hypoalbuminaemia, nephrotic syndrome, hypothyroidism, alcohol abuse, history of hereditary muscular disorder, previous toxicity with other fibrates.
Mild to moderate hepatic and renal impairment.
MONITORING PARAMETERS
Monitor for renal function. Perform periodic LFT every 3 months for the 1st year of treatment.
Monitor for serum creatine phosphokinase (CPK) levels of patients reporting unexplained muscle pain, tenderness, or weakness.
Consider monitoring liver function and creatine kinase when fibrates are used in combination with a statin.
Pregnancy-Lactation
Pregnancy
There is no evidence that ciprofibrate is teratogenic, but signs of toxicity at high doses were observed in teratogenicity tests in animals. As there are no data on its use in human pregnancy, ciprofibrate is contraindicated during pregnancy.
Lactation
Ciprofibrate is excreted in the breast milk of lactating rats. As there are no data on its use in lactation, ciprofibrate is contraindicated in nursing mothers.
Interactions
Increased risk of muscle effects esp rhabdomyolysis w/ HMG-CoA reductase inhibitors. Reduced absorption w/ cholestyramine and colestipol. May increase the effects of phenytoin, tolbutamide and other sulphonylurea derivatives, and coumarin-like anticoagulants. May potentiate the effect of warfarin.
Potentially Fatal: Increased risk of rhabdomyolysis and myoglobinuria w/ other fibrates.
Adverse Effects
Side effects of Ciprofibrate :
Urticaria, rashes, pruritus, eczema; elevated CPK levels, myalgia, myositis; headache, vertigo; nausea, vomiting, anorexia, diarrhoea, dyspepsia, abdominal pain; thrombocytopenia.
Rarely, photosensitivity, alopecia, rhabdomyolysis, dizziness, somnolence, impotence, cholestasis, cytolysis, pneumonitis, pulmonary fibrosis, fatigue, leukocytopenia, pancreatitis, peripheral neuropathy.
Mechanism of Action
Ciprofibrate is a fibric acid derivative that has a marked hypolipidaemic action. It reduces both LDL and VLDL cholesterols, leading to reduced levels of triglycerides, while increasing the HDL cholesterol levels.
Note
Cifirate 100 mg Tablet manufactured by Opsonin Pharma Limited. Its generic name is Ciprofibrate. Cifirate is availble in Bangladesh.
Farmaco BD drug index information on Cifirate Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.